Clonal Mast Cell Disease

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
ScreeningN/A1 trial
Active Trials
NCT07143669Recruiting450Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
Blueprint MedicinesScreening

Clinical Trials (1)

Total enrollment: 450 patients across 1 trials

NCT07143669Blueprint MedicinesScreening

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Start: Oct 2025Est. completion: Oct 2028450 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 450 patients
1 companies competing in this space